Nektar Therapeutics NKTR

NAS: NKTR | ISIN: US6402681083 9/06/2026

56,23 USD (-0,69%)

(-0,69%) 9/06/2026

Grafiek Nektar Therapeutics

Grafiek Nektar Therapeutics

1 dag1d -0,69%
1 week1w -3,98%
1 maand1m -28,57%
3 maanden3m -18,68%
6 maanden6m -4,34%
1 jaar1j 539,70%
5 jaar5j 234,50%

Nektar Therapeutics in het nieuws

Toon enkel gratis nieuws

3 juni 2026 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

28 mei 2026 · Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York · Persbericht

7 mei 2026 · Nektar Therapeutics Reports First Quarter 2026 Financial Results · Persbericht

7 mei 2026 · Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTR · Persbericht

5 mei 2026 · NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 · Persbericht

1 mei 2026 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

1 mei 2026 · Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit · Persbericht

1 mei 2026 · Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTR · Persbericht

30 april 2026 · NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 · Persbericht

29 april 2026 · Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets · Persbericht

Profiel Nektar Therapeutics

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.nektar.com

Hoofdzetel: San Francisco, California Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe